Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo

2857.199 - 2882.811 Dr. Andrea Apolo

And this was basically the safety run-in with the triplet EV, DERVA, TREMI in the neoadjuvant setting and then in the adjuvant setting. And they were really looking at clearance of ctDNA. And they found that There's a pathologic complete response rate, and there's also downstaging of the tumor, and there's clearance of the ctDNA. So that may be a good biomarker for efficacy. So more to come.